NEW YORK (GenomeWeb News) – Roche announced today that its Roche NimbleGen business will collaborate with High Throughput Genomics on gene expression applications.
Under the pact, Roche NimbleGen will provide HTG with high-density, multiplex DNA microarray slides. HTG will apply its quantitative nuclease protection assay process to the arrays to enable researchers to rapidly measure gene expression levels in a variety of sample types.
The firms said that sample preparation using the qNPA technology enables simpler and more cost-effective workflow compared to traditional labeling methods.
"Roche NimbleGen was able to offer us unique and differentiated array synthesis and formatting capabilities that best meet our client needs," T.J. Johnson, president and CEO of Tucson, Az.-based HTG, said in a statement. "The combination of low cost, flexibility, and high throughput means HTG's customers can derive substantial benefits quickly and we can increase the plex in the analysis process as needed."